Status:
RECRUITING
Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease
Lead Sponsor:
Guangzhou University of Traditional Chinese Medicine
Collaborating Sponsors:
Guangzhou Cadre Health Management Center
Conditions:
Alzheimer Disease, Early Onset
Protein; Disease
Eligibility:
All Genders
55+ years
Brief Summary
This study intends to adopt standardized and rigorous cross-sectional research, collect biological specimens (including blood, feces, urine, saliva and tongue coating) from eligible subjects, and use ...
Detailed Description
The problem of population aging is getting worse, the prevalence of senile dementia is increasing, and Alzheimer's disease (AD) is the most common type of dementia. There is no effective treatment for...
Eligibility Criteria
Inclusion
- Older than 55-year-old，male or female.
- patients meet the diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease(AD) or whose family members were diagnoed with AD
- Complete self-rating scale for memory impairment (AD-8 scale)
- Those who agree to participate in clinical research and sign informed consent.
Exclusion
- Patients with acute cardiovascular and cerebrovascular diseases, acute infections (pneumonia, urinary tract infection, oral infection, digestive tract infection), severe renal dysfunction, and uremia;
- Pregnant or lactating women;
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT04804618
Start Date
June 1 2021
End Date
June 30 2026
Last Update
November 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangdong Province Hospital of Tradtional Chinese Medicine
Guangzhou, Guangdong, China, 510120